Skip to main content
Skip to footer
Home
News Channels
All News
Reports
Press Room
Contact Us
About Us
Search ...
All Categories
Antibodies
DNA RNA and Cells
More News
Proteins and Peptides
Small Molecules
Vaccines
Results
Reports
Jul 2023
Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review
300,00€
Jul 2023
Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists
400,00€
Jul 2023
Adalimumab (Humira) Biosimilars Pipeline Review
400,00€
Jun 2023
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review
300,00€
Jun 2023
Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review
300,00€
Jun 2023
Ranibizumab (Lucentis) Biosimilars Pipeline Review
300,00€
Jun 2023
Aflibercept (Eylea) Biosimilars Pipeline Review
300,00€
Jun 2023
Ustekinumab (Stelara) Biosimilars Pipeline Review
300,00€
Jun 2023
TSLP Pipeline Review
300,00€
Mar 2023
2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
120,00€
Feb 2023
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
1.600,00€
Feb 2023
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing
1.800,00€
Nov 2022
RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective
2.350,00€
Jul 2022
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
2.550,00€
1.800,00€
Jul 2022
GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
600,00€
Jun 2022
ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
1.050,00€
May 2022
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities
400,00€
May 2022
Claudin 6: A target opportunity to develop effector-enhanced drug modalities
500,00€
Mar 2022
Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing
2.450,00€
Mar 2022
2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
100,00€
Oct 2021
2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount
4.400,00€
2.200,00€
Oct 2021
Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective
2.250,00€
Jul 2021
Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective
2.150,00€
Mar 2021
2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
100,00€
May 2020
Report Package: “Drug the Undruggable” Technologies
8.250,00€
4.125,00€
←
1
2
3
→
Search ...
Report categories
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells
Drug the Undruggable Technologies
Immuno-Oncology
mRNA Vaccines & Therapeutics
NK Cells & CAR Macrophages
Pipeline Database
RNA-Targeted Therapeutics
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Antibodies
Therapeutic Proteins & Peptides